EFFECT OF FIMASARTAN ON PHARMACOKINETICS IN PATIENTS WITH RENAL IMPAIRMENT.

被引：0
|
作者：
Kim, S. [1 ]
Shin, D. [1 ]
Kim, Y. S. [2 ]
Cho, S. H. [1 ]
Jang, I. J. [1 ]
Lee, H. [1 ]
Yu, K. S. [1 ]
机构：
[1] Seoul Natl Univ, Dept Clin Pharmacol & Therapeut, Coll Med & Hosp, Seoul, South Korea
[2] Seoul Natl Univ, Dept Internal Med, Coll Med & Hosp, Seoul, South Korea
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics of frovatriptan in patients with renal impairment.
    Cohen, AF
    van der Post, J
    Sacks, S
    Marsh, J
    Buchan, P
    [J]. CEPHALALGIA, 1999, 19 (04) : 365 - 365
  • [2] Pharmacokinetics of pioglitazone in patients with renal impairment.
    Edwards, G
    Eckland, DJA
    [J]. DIABETOLOGIA, 1999, 42 : A230 - A230
  • [3] Pharmacokinetics of eslicarbazepine acetate in patients with renal impairment.
    Almeida, Luis
    Potgieter, J. Henk
    Maia, Joana
    Soares-da-Silva, P.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1193 - 1193
  • [4] The Pharmacokinetics of Voclosporin (VCS) in Renal Impairment.
    Freitag, D.
    Huizinga, R.
    Mayo, P.
    Ling, S.
    Foster, R.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 335 - 335
  • [5] Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment.
    Jacobsen, LV
    Popescu, G
    Plum, A
    [J]. DIABETOLOGIA, 2002, 45 : A259 - A260
  • [6] Pharmacodynamics and pharmacokinetics of DX-9065a in renal impairment.
    Depasse, F
    Kunitada, S
    Busson, J
    Haque, N
    Samama, MM
    [J]. BLOOD, 2003, 102 (11) : 121B - 121B
  • [7] Pharmacokinetics of zileuton and its metabolites in subjects with renal impairment.
    Awni, WM
    Wong, S
    Chu, SY
    Patterson, K
    Hansen, R
    Machinist, JM
    Drajesk, J
    Keane, WF
    Halstenson, CE
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII90 - PII90
  • [8] Pharmacokinetics and safety of telithromycin after single and multiple doses in patients with renal impairment.
    Shi, J
    Montay, G
    Chapel, S
    Hardy, P
    Barrett, J
    Sack, M
    Marbury, T
    Swan, S
    Vargas, R
    Leclerc, V
    Leroy, B
    Bhargava, V
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P35 - P35
  • [9] The pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran in patients with severe renal impairment.
    Eriksson, UG
    Samuelsson, O
    Attman, PO
    Mulec, H
    Johausson, S
    Frison, L
    Fager, G
    [J]. BLOOD, 2001, 98 (11) : 268A - 268A
  • [10] Eribulin mesylate pharmacokinetics in patients with hepatic impairment.
    Witteveen, P.
    Marchetti, S.
    Mergui-Roelvink, M.
    Reyderman, L.
    Copelu, W.
    Wanders, J.
    Jenner, A.
    Edwards, G.
    Schellens, J. H.
    Voest, E. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345